A group of scientists has discovered how and why certain Covid-19 users suffer potentially deadly blood clots.

The equilibrium between a molecule that induces clotting called the von Willebrand Factor (VWF) and its regulator, ADAMTS13, was found to be significantly disturbed in Covid patients who had increased levels of the VWF protein, according to researchers from the Royal College of Surgeons in Ireland (RCSI).

The ADAMTS13 gene codes for an enzyme that influences blood clotting, whereas VWF is a big multimeric glycoprotein present in plasma. VWF deficiency or malfunction can cause either bleeding or thrombosis.

Based on the current reports by BBC, the discoveries might lead to tailored treatments that prevent similar clots from occurring in the future. The findings have also been reported in the Journal of Thrombosis and Haemostasis.

"Our research will contribute to understanding the processes that produce severe blood clots in Covid-19 patients, which would be essential in identifying more targeted treatment," stated Dr. Jamie O'Sullivan, a research lecturer at the RCSI.

She stated that additional study was required to understand whether objectives focused on correcting ADAMTS 13 and VWF levels could result in beneficial treatments.

"We must continue to find treatments for Covid-19 patients," O'Sullivan added.

"Vaccines would continue to be inaccessible to many people throughout the world, so it is critical that we give targeted treatment to these people, and also those with emerging infections," she said.

The scientists analyzed samples from Covid-19 patients in intensive care at Dublin's Beaumont Hospital for the study.